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Abstract
Background—Most measures of fecal incontinence (FI) severity assess the frequency of solid 
and liquid FI, but may incorporate other features. We compared two scales – the Fecal 
Incontinence Severity Score (FISS) and Fecal Incontinence Severity Index (FISI) – to determine 
which questionnaire and which individual questions predict FI Quality of Life (FIQOL).
Methods—A national sample of American adults completed a health questionnaire, and 234 with 
monthly FI were selected. Participants completed assessments of FI severity, FIQOL, and 
somatization. Stepwise linear regression models evaluated whether FISS and FISI total scores, or 
individual items on the FISS and FISI predicted FIQOL after adjusting for gender, age, income, 
and somatization (Brief Symptom Inventory-18).
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Key Results—Reliable responses were provided by 186. Age was 49 years, and 52% were 
women. The mean FISS score was 8.4 (95% Confidence Interval (CI) 8.0-8.9, 13 questions) and 
mean FISI was 29.9 (95% CI 27.4-32.4, 62 questions), indicating moderate FI severity. The mean 
FIQOL was 2.6 (95% CI 2.4-2.7, 5 questions). Lower income, greater somatization, and total FISS 
and FISI scores explained 69% of FIQOL; and total FISS and FISI scores were independent 
predictors. On the FISS, frequency, amount, and urgency to defecate were independently 
associated with FIQOL. After adding somatization, all but amount remained significant. For the 
FISI scale, solid and liquid FI and gas were significant predictors, but adjusting for somatization 
excluded solid FI.
Conclusions and Inferences—Five variables independently explained FIQOL: overall 
frequency of FI, frequency of liquid and gas leakage, urgency, and somatization.
Graphical abstract
We compared two commonly used scales of the severity of fecal incontinence to determine which 
is the best predictor of disease-specific quality of life (Rockwood Fecal Incontinence Quality of 
Life Scale). The two scales are the Fecal Incontinence Severity Scale and the Fecal Incontinence 
Severity Index.
Fecal incontinence (FI) is a psychologically and socially debilitating condition that can lead 
to embarrassment, social isolation, loss of self-confidence, and even depression1. These 
consequences contribute to the well-documented lower quality of life reported by individuals 
with the disorder2. The prevalence of FI is 7-15% in noninstitutionalized U.S. adults3, 
demonstrating a wide burden on patients, families, caregivers, and communities.
FI is defined as the involuntary loss of solid or liquid feces or mucus. A National Institute of 
Diabetes and Digestive Kidney Diseases (NDDK) conference in 2013 identified the need for 
research to evaluate the psychometric properties of instruments for evaluating symptom 
severity and quality of life in FI3. There are several published scales to determine the 
severity of incontinence, but they differ as to whether they discriminate between the types of 
stool loss, the volume of stool loss, whether urgency was present preceding the incontinence, 
and whether individuals used pads or other methods for preventing or managing FI. 
Currently, it is unknown whether these severity measures of FI are assessing the same thing 
(i.e., how well they correlate with each other), and which is the most sensitive and specific 
for FI.
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One approach to answering these questions was to compare FI severity scales to an external 
standard – the Fecal Incontinence Quality of Life Scale (FIQOL)5. The severity of FI 
symptoms correlates with its impact on QOL in a cross-sectional survey6. In this study our 
aims were to test which of two commonly used FI severity scales – the Fecal Incontinence 
Severity Index (FISI)7 and the Fecal Incontinence Severity Score (FISS), which was 
previously known as the Fecal Incontinence and Constipation Assessment scale8 – is the 
better predictor of the impact of FI on the patient’s quality of life5. We also sought to 
determine which questions within these instruments are best able to predict variations in 
reported FIQOL impact. This study may ultimately help us develop more sensitive and 
specific scales to measure FI severity.
Materials and Methods
This is a descriptive study of a single cohort of people identified in an internet survey as 
having FI. The study’s objectives were addressed using a nationally representative sample of 
patients with FI who were identified from the registry of a market-research company (Cint 
USA, Inc., Lawrenceville, New Jersey). The Internet survey included the FISI7, the FISS8, 
and FIQOL9 questionnaires.
The FISI assesses FI over the previous month and consists of 4 questions about the 
frequency of different types of FI – solid, liquid, mucus, and gas1 – on an ordinal scale with 
response options of “Never”, “1-3 times a month”, “once a week”, “2 or more times a 
week”, “once a day”, or “2 or more times a day”. However, a specific frequency of leaking 
stool may have more or less impact on the patient’s life depending on the consistency of the 
stool that is lost. For example, losing liquid stool twice a week may have more impact than 
losing gas twice a week. Consequently, the test developers provided two sets of “weights” 
for each possible response: weights based on the average ratings of a group of 34 patients 
with FI, or the average ratings of a group of 26 colorectal surgeons. Patients or surgeons 
were instructed to rate the frequency of each type of FI (gas, mucus, liquid stool, solid stool) 
on a grid showing the frequency of occurrence. They were then asked to assign a rating to 
each category with 20 representing the most severe FI and 1 representing the least severe. 
The average ratings were calculated for each cell in the table. When a subject completed the 
questionnaire, the average weight assigned by reference patients (or surgeons) was 
substituted for their response, and these numbers were added together. The score could range 
from 0 to 61. In our opinion, patients are better able to judge the subjective qualities (e.g., 
embarrassment) of different types of FI than are physicians, so we used the patient weights 
rather than physician weights to compute the total FISI score.
The second severity scale, the FISS, includes 5 questions: frequency of FI in the last year, 
type of FI (i.e., stool only, liquid or mucus only, both liquid/mucus and stool, or gas only), 
amount of stool leaked (i.e., small, moderate, or large amount), frequency of having to rush 
to the toilet, and frequency of having stool leakage without any warning. The fourth and fifth 
questions are merged to determine whether the patient has passive FI (i.e., FI without any 
warning), urge FI, both, or neither. The responses to these four questions are assigned 
physician-derived weights and added together for a total severity score ranging from 4 to 13.
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The FIQOL questionnaire5 consists of 29 questions to assess the patient’s quality of life. 
There are four scales: lifestyle (10 questions), coping/behavior (9 questions), depression/
self-perception (7 questions), and embarrassment (3 questions). The response choices are (1) 
“Most of the time”, (2) “Some of the time”, (3) “A little of the time”, (4) “None of the time”, 
and (5) “Not applicable”. Lower numbered responses indicate a poorer QOL. A mean score 
was calculated for each scale (excluding items marked “not applicable”). The FIQOL total 
score was calculated by averaging the responses for all four scales. This was done because 
the subscales of the FIQOL are highly correlated with each other (Pearson r= 0.72-0.88) and 
because this provided a single dependent measure for regression analysis.
The Brief Symptom Inventory9 is a self-report inventory designed to assess the 
psychological symptoms of individuals. The short version of this questionnaire, called the 
Brief Symptom Inventory 18 (BSI-18) because it contains 18 questions, was used in this 
study. It measures 3 primary symptom dimensions (anxiety, depression, and somatization); 
and the subscale of particular interest for this study was the somatization (SOM) domain. 
This subscale measures the psychological tendency to report more bodily symptoms and to 
interpret them as distressing. Each symptom is rated on a 5-point scale (0-4) of distress 
during the previous week, ranging from ‘not-at-all’ to ‘extremely’. The SOM scale was 
included as a covariate in the analyses to test whether estimates of the effects of FI severity 
on FIQOL were confounded by a general tendency to endorse more symptoms.
The health and continence status of people within the internet registry of survey respondents 
was unknown. Invitations extended to potential subjects described the study as a health 
survey in order to minimize possible bias due to self-selection for participation. Screening 
questions were included in the invitation to determine potential subjects with FI at least once 
a month. Quota sampling was employed to recruit approximately equal numbers of 
participants with and without FI, equal numbers of males and females, 60% Caucasians, 
20% Hispanics, and 20% African Americans, and balanced age strata (i.e., 40% aged 20-40 
years, 40% aged 41-60 years, 20% aged 61+).
The survey included 43 to 53 questions, dependent upon branching, and participants 
required approximately 20 minutes to complete the questionnaires. Two questions from the 
first section of the interview were repeated near the end for quality control. Subjects whose 
responses to the repeated questions differed by more than one step on a five-point ordinal 
scale were considered unreliable and were excluded from analysis.
Descriptive statistics including means, standard deviations, and correlations with 
demographic variables were used to address the aims of this study. Statistical analyses 
employed SPSS version 25 software. Stepwise linear regression identified independent 
predictive variables of FIQOL. Demographic variables were entered as a block in the first 
step, followed by the FISS, the FISI, and lastly the somatization scale of the Brief Symptom 
Inventory. A p-value of <0.05 was considered statistically significant. The regression was 
then repeated with individual items from the FISS and the FISI to identify which questions 
from each scale best explained FIQOL.
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The Institutional Review Committee for the Protection of Human Research Participants at 
the University of North Carolina reviewed this study, and approved it by expedited review 
because all the data were collected anonymously.
Results
Two hundred thirty four individuals with FI completed the survey. Forty-eight (20.5%) were 
considered unreliable and were excluded because they gave inconsistent responses to repeat 
questions used for quality control. Of the 186 individuals remaining for analysis, 97 (52%) 
were women and 89 (48%) were men. The average age was 49 years (range 20-91 years). 
Approximately 40% of people surveyed had post-baccalaureate education. Hispanic subjects 
represented 9% of the study population and non-Hispanic black subjects represented 8%. 
Table 1 shows demographic characteristics of all participants. Note that the sample quotas 
for black race and Hispanic ancestry were not filled with the targeted numbers (20% of 
each) because relatively few subjects in these categories with self-reported FI were available 
in the pool of subjects maintained by the internet survey provider.
The average FIQOL score, on a 1-5 scale with 1 indicating a lower quality of life, was 2.57 
(95% CI 2.44-2.69), the mean FISI score was 29.9 (95% CI 27.4-32.4) on a 0-61 scale, and 
the average FISS score on a 1-13 scale was 8.4 (95% CI 8.0-8.9), indicating moderate 
severity. Higher scores on both the FISS and the FISI scales represent greater FI symptom 
severity. The average somatization T-score was 65.6 (95% CI 63.7-67.5). A T-score of 50 is 
representative of the population mean, and a standard deviation of 10 points above or below 
the mean T-score is equivalent to one SD, so a T-score of 65.6 is 1.56 standard deviations 
above the mean for the population.
In the initial regression analysis, demographic factors accounted for an R2 of .269 of the 
variance observed in the combined FIQOL measure. Adding the FISS increased the R2 to .
617, and adding the FISI increased the R2 to .666. The change in R2 was significant at each 
step by ratio of F-values. In the last stage of the regression analysis, adding the somatization 
scale modifier to the model increased R2 to .690. The FISI and FISS both made significant 
contributions (p≤.001) to FIQOL even after adjusting for the confounding effect of 
somatization.
The utility of independent questions of FI severity for predicting the FIQOL was evaluated 
in Table 2. The initial models (Models 1 and 3, Table 2) incorporated demographic features 
and FI severity questions from the FISS and FISI instruments. Thereafter, somatization 
scores were added to these models (Models 2 and 4, Table 2). Model 1 demonstrates that 
age, the frequency of FI, amount of stool lost, and the presence of urge sensation (i.e., urge 
FI, passive FI, combined, or neither urge nor passive FI) evaluated with FISS were 
independently associated with FIQOL. After somatization was added to the model (Model 2, 
Table 2), frequency of FI and passive/urgent FI remained significant, as well as 
somatization. Model 3 in Table 2 shows the first step in the analysis of the FISI scale. In 
addition to sex and age, solid FI, liquid FI, and gas FI from the FISI scale independently 
predicted FIQOL. When somatization was added to the FISI model in Model 4, the 
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frequency of solid stool FI was no longer a significant predictor. Greater somatization scores 
were associated with a lower FIQOL with FISS (Model 2) and FISI (Model 4).
Although the volume of stool lost was not a significant independent predictor of FIQOL 
after adjusting for somatization, we evaluated its association with FIQOL because some 
investigators believe it is a critical dimension of FI severity3. As shown in Figure 1, 
individuals who reported a small amount of FI (staining only) had significantly (p<.001) 
higher FIQOL scores (i.e., lower impact) than those who lost a moderate amount, and those 
who experienced the loss of a moderate amount had significantly higher FIQOL scores (p<.
001) than those who experienced the loss of a full bowel movement. However, after 
multivariate adjustment for other risk variables, the association between volume of stool loss 
and FIQOL was no longer significant (p=. 272).
Additional post hoc analyses were carried out to understand how to explain the discrepancy 
between the univariate analysis of FI volume and the failure to find a significant effect of 
volume in the final regression analysis after adding somatization. This might have occurred 
if the sample contained a disproportionate number of individuals with staining only, so we 
calculated the number of individuals with staining only (n=69), moderate volume FI (n=58), 
and large volume FI (n=59) and found no significant differences. An alternative explanation 
is that the volume of stool loss failed to be significant after multivariate adjustment because 
it was highly correlated with other variables that predict FIQOL. This was confirmed: the 
volume of stool loss was significantly correlated with the overall frequency of FI (rho=.604), 
the frequency of liquid stool FI (rho=.632), and the frequency of urgency (rho=.665; p<.001 
in all three comparisons).
Discussion
In this study, a national sample of US adults showed that both the FISS and FISI are 
significant independent predictors of FIQOL even after taking into account somatization. 
The significant independent predictors of a negative impact on FIQOL are overall frequency 
of FI, the consistency of the lost stool, the frequency of liquid FI, and whether the FI is urge-
related or passive. If one has to choose between these two measures, the FISS has the 
advantage of a larger beta coefficient than the FISI, but the important point is that these two 
measures both make independent contributions to FIQOL.
The second aim of our study was to show the relative predictive value of each question on 
these scales to provide insights into why these two scales are independent predictors of 
FIQOL: The FISS includes the symptoms of urgency, which is strongly associated with 
FIQOL10, and also includes volume of stool loss which is significantly associated with 
FIQOL in univariate tests. The FISI does not include these symptoms.
Conversely, the FISI assigns greater weight to liquid stool loss whereas the FISS assigns 
greater weight to solid than to liquid stool loss in computing the FISS severity score. This 
difference is significant because Rockwood has shown that patients report a greater quality 
of life impact score to liquid than to solid stool loss. By contrast, surgeons assign a greater 
impact score to solid compared to liquid FI because leakage of solid stool generally reflects 
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more severe anal weakness. The frequency of liquid stool FI was more strongly associated 
with FIQOL than solid stool FI (Table 2, Model 1). In the future, scoring instructions for the 
FISS could be modified to invert scores for solid and liquid FI.
Another important distinction between the two scales is the time-frame for reporting 
symptoms: the last month for the FISI and the last year for the FISS. A consequence of this 
difference is that the FISI is better able to tell whether the subject is currently symptomatic 
and perhaps better able to detect the impact of treatment whereas the FISS is more likely to 
identify patients with intermittent FI. (The instructions for the FISS can be modified to 
request subjects to report on the previous month or the previous week in order to use this 
scale as an outcome measure in treatment studies11).
Many investigators believe that amount of FI is a major determinant of quality of life impact 
of FI. In this cohort, the amount of FI independently predicted the quality of life before but 
not after adjusting for somatization. For this reason we evaluated the univariate association 
of FI volume with FIQOL (Figure 1) and found that individuals who experienced only 
staining reported significantly better FIQOL scores (i.e., less impact from FI) than 
individuals who experienced moderate volumes of stool loss, and that individuals with 
moderate volumes of loss in turn had a significantly better quality of life than those who had 
large volume FI (full bowel movement). Post hoc analyses to explain the discrepancy 
between the univariate and the multivariate analyses of the relationship between FI volume 
and FIQOL showed that this could not be explained by a disproportionate number of 
individuals with staining only in the sample. Instead we found that the discrepancy was due 
to high correlations between volume of stool loss and other variables that were strongly 
associated with FIQOL, namely overall frequency of FI, frequency of liquid stool FI, and 
frequency of strong urge sensations preceding FI. More research is needed to evaluate how 
volume of FI should be incorporated into measures of FI severity12.
Comorbid conditions that influence FI Quality of Life
Other studies13 show that older age is significantly associated with an increased prevalence 
of FI, so we investigated whether it contributed to the impact of FI on quality of life. In this 
study, it did not. However, it is possible that our quality of life measures are related to other 
age effects such as whether the individual is retired or sill working. Future studies will need 
to address this.
While somatization is associated with functional GI disorders14, 15, to our knowledge, the 
contribution of somatization to FIQOL has not been recognized hitherto. Perhaps this 
explains the limited correlation between FI symptom severity and FIQOL in some studies16 
and underscores the importance of considering somatization when interpreting FIQOL.
Study limitations
Responses from 20% of individuals were considered unreliable and excluded from the 
survey. Individuals who had completed post-baccalaureate education were over represented 
(39.2%) in this sample, and educational level is associated with increased consultations for 
functional GI symptoms17. However, our primary aims were to determine which severity 
scales and which components of those scales are the most strongly associated with FIQOL, 
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and there is no reason to believe the generalizability of these associations would be limited 
to more highly educated patients.
Another limitation of this study was that only the FISS and FISI severity scales were 
evaluated while other frequently used questionnaires18 such as the Wexner (Cleveland Clinic 
Florida) and the Vaizey scales were omitted. The Wexner and Vaizey scales both have 
components that assess pad usage and lifestyle alteration (i.e., coping behaviors). It was 
decided that these questionnaires would not be included in this study because the use of pads 
could reflect the patients’ fastidiousness19 rather than the severity of FI.
Another limitation of our study is that we did not take the unpredictability of FI events into 
account when assessing symptoms which influence FIQOL. Sung and colleagues12 
identified this as an important component of FI severity in focus groups which they 
conducted. This symptom should be incorporated into future studies directed towards the 
development of improved FI severity measures. Lastly, as a consequence of selecting only 
patients with at least one episode of solid or liquid stool per month, most of these subjects 
had moderately severe FI; none had mild or severe FI, which comprise 43% and 5% of 
women with FI in the community6.
Conclusions
This study shows that, if one has to choose a single measure of FI severity, the FISS has 
advantages over the FISI, although both have their strengths and they make independent 
contributions to the prediction of FIQOL. The most important contributions of this study are 
the identification of which symptom questions are the most strongly associated with FIQOL 
because this should enable investigators to design more sensitive and reliable measures of FI 
severity than either the FISS or the FISI. If clinicians or clinical investigators choose to use 
the FISS as a measure of treatment efficacy, they should modify the time interval for 
reporting to the last month.
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• Several scales measure the severity of fecal incontinence (FI), but the best 
measure is unknown. We compared two commonly used scales to assess how 
well they predict the impact of FI on quality of life.
• Both scales are independent predictors of quality of life. Specific symptoms 
were overall frequency, liquid and gas frequency, and urgency. Somatization 
(awareness of many symptoms) is a strong contributor.
• These data may enable us to develop more sensitive and reliable measures of 
FI severity.
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Association between volume of FI and FIQOL. Larger FI volume was associated with lower, 
i.e., worse, FIQOL (* p < .001).
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Table 1
Characteristics of the Sample
Total
n (%)
Total Sample 186 (100)
Gender
 Female 97 (52.1)
 Male 89 (47.8)
Age (years)
 Up to 35 50 (26.9)
 Over 35 Less than 65 94 (50.5)
 65 and Older 42 (22.6)
Race
 White/Caucasian (non-Hispanic) 154 (82.8)
 Black/African American (non-Hispanic) 15 (8.1)
 Hispanic (of any Race) 17 (9.1)
Education
 High school 27 (14.5)
 College 86 (46.2)
 Postgraduate 73 (39.3)
Respondents with missing data and responses of “refused” and “don’t know” were excluded from the table
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Table 2
Contribution of Demographic Features, FI Attributes, and Somatization on FIQOL1
Parameter Model 12 Model 22






Relationship/marital status −.022 −.035
Frequency of FI −.2355 −.2165
Amount of FI −.2044 −.113
Composition of FI −.031 −.007
Urgency/passive FI −.4625 .3445
Somatization NA −.3535
Total Adjusted R2 0.644 0.693






Relationship/marital status −.020 −.044
Solid stool FI −.2404 −.1153
Liquid stool FI −.4295 −.330 5
Mucus stool FI −.044 −.001
Gas – FI −.2135 −.1624
Somatization NA −.3675
Total Adjusted R2 0.606 0.655
1
Values are standardized β coefficients. Negative values imply that greater values for the attribute (eg, frequency of FI) are associated with lower 
values for FIQOL (i.e., poorer FIQOL)
2
In addition to demographic features, Models 1 and 3 incorporate attributes of FI as characterized respectively by the FISS and FISI scales. In 
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